1. Home
  2. XBIT vs JRVR Comparison

XBIT vs JRVR Comparison

Compare XBIT & JRVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XBiotech Inc.

XBIT

XBiotech Inc.

SELL

Current Price

$2.22

Market Cap

69.8M

Sector

Health Care

ML Signal

SELL

Logo James River Group Holdings Ltd.

JRVR

James River Group Holdings Ltd.

SELL

Current Price

$3.71

Market Cap

209.9M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
XBIT
JRVR
Founded
2005
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
69.8M
209.9M
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
XBIT
JRVR
Price
$2.22
$3.71
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
★ $4.72
AVG Volume (30 Days)
32.2K
★ 295.5K
Earning Date
11-11-2026
11-02-2026
Dividend Yield
N/A
★ 1.09%
EPS Growth
N/A
★ 125.82
EPS
N/A
★ N/A
Revenue
N/A
★ $687,614,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$30.47
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$2.09
$3.36
52 Week High
$3.44
$7.20

Technical Indicators

Market Signals
Indicator
XBIT
JRVR
Relative Strength Index (RSI) 51.97 53.07
Support Level $2.15 $3.36
Resistance Level $2.46 $4.26
Average True Range (ATR) 0.05 0.10
MACD 0.01 0.05
Stochastic Oscillator 45.00 87.50

Price Performance

Historical Comparison
XBIT
JRVR

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

About JRVR James River Group Holdings Ltd.

James River Group Holdings Inc is a holding company that owns and operates a group of specialty insurance companies focused on underwriting small and middle market casualty risks within the U.S. excess and surplus (E&S) lines market. The Company operates in two specialty property-casualty insurance segments: Excess and Surplus Lines and Specialty Admitted Insurance.

Share on Social Networks: